Allurion Technologies (ALUR) announced that it has entered into a definitive securities purchase agreement with certain institutional investors ...

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...

The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

Allurion Technologies (NYSE:ALUR) climbed 200% in the morning hours on Friday, adding to its strong post-market gains yesterday, even after the weight loss product developer announced plans to ...

NATICK, Mass., February 20, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...